Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/28038
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Livermore, D. | - |
dc.contributor.author | Carter, M. | - |
dc.contributor.author | Bagel, S. | - |
dc.contributor.author | Wiedemann, B. | - |
dc.contributor.author | Baquero, F. | - |
dc.contributor.author | Loza, E. | - |
dc.contributor.author | Endtz, H. | - |
dc.contributor.author | van den Braak, N. | - |
dc.contributor.author | Fernandes, C. | - |
dc.contributor.author | Fernandes, L. | - |
dc.contributor.author | Frimodt-Moller, N. | - |
dc.contributor.author | Rasmussen, L. | - |
dc.contributor.author | Giamarellou, H. | - |
dc.contributor.author | Giamarellos-Bourboulis, E. | - |
dc.contributor.author | Jarlier, V. | - |
dc.contributor.author | Nguyen, J. | - |
dc.contributor.author | Nord, C. | - |
dc.contributor.author | Struelens, M. | - |
dc.contributor.author | Nonhoff, C. | - |
dc.contributor.author | Turnidge, J. | - |
dc.contributor.author | et al. | - |
dc.date.issued | 2001 | - |
dc.identifier.citation | Antimicrobial Agents and Chemotherapy, 2001; 45(6):1860-1867 | - |
dc.identifier.issn | 0066-4804 | - |
dc.identifier.issn | 1098-6596 | - |
dc.identifier.uri | http://hdl.handle.net/2440/28038 | - |
dc.description.abstract | Ertapenem (MK-0826, L-749,345) is a 1-β-methyl carbapenem with a long serum half-life. Its in vitro activity was determined by broth microdilution against 3,478 bacteria from 12 centers in Europe and Australia, with imipenem, cefepime, ceftriaxone, and piperacillin-tazobactam used as comparators. Ertapenem was the most active agent tested against members of the familyEnterobacteriaceae, with MICs at which 90% of isolates are inhibited (MIC₉₀s) of ≤1 μg/ml for all species. Ertapenem also was more active than imipenem against fastidious gram-negative bacteria and Moraxella spp.; on the other hand, ertapenem was slightly less active than imipenem against streptococci, methicillin-susceptible staphylococci, and anaerobes, but its MIC₉₀s for these groups remained ≤0.5 μg/ml.Acinetobacter spp. and Pseudomonas aeruginosawere also much less susceptible to ertapenem than imipenem, and mostEnterococcus faecalis strains were resistant. Ertapenem resistance, based on a provisional NCCLS MIC breakpoint of ≥16 μg/ml, was seen in only 3 of 1,611 strains of the familyEnterobacteriaceae tested, all of them Enterobacter aerogenes. Resistance was also seen in 2 of 135 anaerobes, comprising 1 Bacteroides fragilis strain and 1Clostridium difficile strain. Ertapenem breakpoints for streptococci have not been established, but an unofficial susceptibility breakpoint of ≤2 μg/ml was adopted for clinical trials to generate corresponding clinical response data for isolates for which MICs were as high as 2 μg/ml. Of 234 Streptococcus pneumoniae strains tested, 2 required ertapenem MICs of 2 μg/ml and one required an MIC of 4 μg/ml, among 67 non-Streptococcus pyogenes, non-Streptococcus pneumoniae streptococci, single isolates required ertapenem MICs of 2 and 16 μg/ml. These streptococci also had diminished susceptibilities to other β-lactams, including imipenem as well as ertapenem. The Etest and disk diffusion gave susceptibility test results in good agreement with those of the broth microdilution method for ertapenem. | - |
dc.description.statementofresponsibility | David M. Livermore, Michael W. Carter, Simone Bagel, Bernd Wiedemann, Fernando Baquero, Elena Loza, Hubert P. Endtz, Nicole Van Den Braak, Clarence J. Fernandes, Lorna Fernandes, Niels Frimodt-Moller, Laura S. Rasmussen, Helen Giamarellou, Evangelos Giamarellos-Bourboulis, Vincent Jarlier, Jacqueline Nguyen, Carl-Erik Nord, Marc J. Struelens, Caire Nonhoff, John Turnidge, Jan Bell, Reinhard Zbinden, Stefan Pfister, Lori Mixson, and Daniel L. Shungu | - |
dc.language.iso | en | - |
dc.publisher | Amer Soc Microbiology | - |
dc.rights | Copyright © 2000, American Society for Microbiology. All Rights Reserved. | - |
dc.source.uri | http://dx.doi.org/10.1128/aac.45.6.1860-1867.2001 | - |
dc.subject | Bacteria | - |
dc.subject | Carbapenems | - |
dc.subject | Anti-Bacterial Agents | - |
dc.subject | Microbial Sensitivity Tests | - |
dc.subject | Quality Control | - |
dc.subject | Australia | - |
dc.subject | Europe | - |
dc.title | In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1128/AAC.45.6.1860-1867.2001 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Turnidge, J. [0000-0003-4240-5578] | - |
Appears in Collections: | Aurora harvest 6 Molecular and Biomedical Science publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.